S&P 500   3,873.58 (-0.72%)
DOW   31,409.95 (-0.40%)
QQQ   319.26 (-1.34%)
AAPL   125.62 (-1.70%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,108.39 (-1.20%)
NVDA   539.35 (-2.59%)
BABA   235.64 (-2.50%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.13 (-13.32%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.61 (+5.26%)
ACB   11.06 (+0.18%)
DIS   194.16 (-0.42%)
BA   223.93 (-0.21%)
NFLX   551.01 (+0.07%)
BAC   35.66 (-0.36%)
S&P 500   3,873.58 (-0.72%)
DOW   31,409.95 (-0.40%)
QQQ   319.26 (-1.34%)
AAPL   125.62 (-1.70%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,108.39 (-1.20%)
NVDA   539.35 (-2.59%)
BABA   235.64 (-2.50%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.13 (-13.32%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.61 (+5.26%)
ACB   11.06 (+0.18%)
DIS   194.16 (-0.42%)
BA   223.93 (-0.21%)
NFLX   551.01 (+0.07%)
BAC   35.66 (-0.36%)
S&P 500   3,873.58 (-0.72%)
DOW   31,409.95 (-0.40%)
QQQ   319.26 (-1.34%)
AAPL   125.62 (-1.70%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,108.39 (-1.20%)
NVDA   539.35 (-2.59%)
BABA   235.64 (-2.50%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.13 (-13.32%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.61 (+5.26%)
ACB   11.06 (+0.18%)
DIS   194.16 (-0.42%)
BA   223.93 (-0.21%)
NFLX   551.01 (+0.07%)
BAC   35.66 (-0.36%)
S&P 500   3,873.58 (-0.72%)
DOW   31,409.95 (-0.40%)
QQQ   319.26 (-1.34%)
AAPL   125.62 (-1.70%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,108.39 (-1.20%)
NVDA   539.35 (-2.59%)
BABA   235.64 (-2.50%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.13 (-13.32%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.61 (+5.26%)
ACB   11.06 (+0.18%)
DIS   194.16 (-0.42%)
BA   223.93 (-0.21%)
NFLX   551.01 (+0.07%)
BAC   35.66 (-0.36%)
Log in
NASDAQ:LIXT

Lixte Biotechnology Competitors

$4.13
-0.35 (-7.81 %)
(As of 03/2/2021 03:42 PM ET)
Add
Compare
Today's Range
$4.10
Now: $4.13
$4.59
50-Day Range
$3.05
MA: $3.54
$5.58
52-Week Range
$3.00
Now: $4.13
$7.86
Volume8,221 shs
Average Volume1.50 million shs
Market Capitalization$51.10 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.15

Competitors

Lixte Biotechnology (NASDAQ:LIXT) Vs. NEPT, ITRM, SBBP, CNCE, OPTN, and TLSA

Should you be buying LIXT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Lixte Biotechnology, including Neptune Wellness Solutions (NEPT), Iterum Therapeutics (ITRM), Strongbridge Biopharma (SBBP), Concert Pharmaceuticals (CNCE), OptiNose (OPTN), and Tiziana Life Sciences (TLSA).

Lixte Biotechnology (NASDAQ:LIXT) and Neptune Wellness Solutions (NASDAQ:NEPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Neptune Wellness Solutions has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500.

Profitability

This table compares Lixte Biotechnology and Neptune Wellness Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lixte BiotechnologyN/AN/AN/A
Neptune Wellness Solutions-97.35%-46.39%-37.77%

Valuation and Earnings

This table compares Lixte Biotechnology and Neptune Wellness Solutions' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/AN/AN/AN/A
Neptune Wellness Solutions$22.05 million10.14$-45,760,000.00($0.43)-3.77

Lixte Biotechnology has higher earnings, but lower revenue than Neptune Wellness Solutions.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Neptune Wellness Solutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lixte Biotechnology0000N/A
Neptune Wellness Solutions00103.00

Neptune Wellness Solutions has a consensus target price of $6.00, indicating a potential upside of 263.64%. Given Neptune Wellness Solutions' higher probable upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Lixte Biotechnology.

Summary

Neptune Wellness Solutions beats Lixte Biotechnology on 5 of the 8 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Profitability

This table compares Lixte Biotechnology and Iterum Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lixte BiotechnologyN/AN/AN/A
Iterum TherapeuticsN/AN/A-179.51%

Valuation and Earnings

This table compares Lixte Biotechnology and Iterum Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/AN/AN/AN/A
Iterum Therapeutics$40,000.005,058.01$-103,130,000.00($7.10)-0.24

Lixte Biotechnology has higher earnings, but lower revenue than Iterum Therapeutics.

Institutional & Insider Ownership

10.1% of Iterum Therapeutics shares are owned by institutional investors. 22.1% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Iterum Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lixte Biotechnology0000N/A
Iterum Therapeutics03102.25

Iterum Therapeutics has a consensus target price of $4.8750, indicating a potential upside of 185.09%. Given Iterum Therapeutics' higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Lixte Biotechnology.

Summary

Iterum Therapeutics beats Lixte Biotechnology on 6 of the 7 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

Profitability

This table compares Lixte Biotechnology and Strongbridge Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lixte BiotechnologyN/AN/AN/A
Strongbridge Biopharma-149.79%-65.85%-38.81%

Valuation and Earnings

This table compares Lixte Biotechnology and Strongbridge Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/AN/AN/AN/A
Strongbridge Biopharma$21.71 million9.54$-49,450,000.00($1.10)-2.80

Lixte Biotechnology has higher earnings, but lower revenue than Strongbridge Biopharma.

Institutional & Insider Ownership

58.3% of Strongbridge Biopharma shares are owned by institutional investors. 6.6% of Strongbridge Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Strongbridge Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lixte Biotechnology0000N/A
Strongbridge Biopharma00403.00

Strongbridge Biopharma has a consensus target price of $7.1250, indicating a potential upside of 129.84%. Given Strongbridge Biopharma's higher probable upside, analysts clearly believe Strongbridge Biopharma is more favorable than Lixte Biotechnology.

Summary

Strongbridge Biopharma beats Lixte Biotechnology on 6 of the 9 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Concert Pharmaceuticals (NASDAQ:CNCE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Valuation and Earnings

This table compares Lixte Biotechnology and Concert Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/AN/AN/AN/A
Concert Pharmaceuticals$1.08 million187.87$-78,170,000.00($3.29)-2.01

Lixte Biotechnology has higher earnings, but lower revenue than Concert Pharmaceuticals.

Profitability

This table compares Lixte Biotechnology and Concert Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lixte BiotechnologyN/AN/AN/A
Concert Pharmaceuticals-921.38%-55.20%-44.83%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Concert Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lixte Biotechnology0000N/A
Concert Pharmaceuticals00503.00

Concert Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 208.82%. Given Concert Pharmaceuticals' higher probable upside, analysts clearly believe Concert Pharmaceuticals is more favorable than Lixte Biotechnology.

Summary

Concert Pharmaceuticals beats Lixte Biotechnology on 6 of the 9 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Volatility & Risk

OptiNose has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -1.15, indicating that its share price is 215% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for OptiNose and Lixte Biotechnology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptiNose01202.67
Lixte Biotechnology0000N/A

OptiNose currently has a consensus price target of $19.00, indicating a potential upside of 381.01%. Given OptiNose's higher possible upside, research analysts plainly believe OptiNose is more favorable than Lixte Biotechnology.

Earnings and Valuation

This table compares OptiNose and Lixte Biotechnology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiNose$34.63 million5.96$-110,050,000.00($2.63)-1.51
Lixte BiotechnologyN/AN/AN/AN/AN/A

Lixte Biotechnology has lower revenue, but higher earnings than OptiNose.

Insider and Institutional Ownership

62.9% of OptiNose shares are owned by institutional investors. 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Lixte Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptiNose-230.14%-294.64%-59.29%
Lixte BiotechnologyN/AN/AN/A

Summary

OptiNose beats Lixte Biotechnology on 6 of the 9 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Risk & Volatility

Lixte Biotechnology has a beta of -1.15, suggesting that its stock price is 215% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Lixte Biotechnology and Tiziana Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lixte Biotechnology0000N/A
Tiziana Life Sciences00203.00

Tiziana Life Sciences has a consensus price target of $9.50, indicating a potential upside of 186.14%. Given Tiziana Life Sciences' higher possible upside, analysts clearly believe Tiziana Life Sciences is more favorable than Lixte Biotechnology.

Valuation and Earnings

This table compares Lixte Biotechnology and Tiziana Life Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/AN/AN/AN/A
Tiziana Life SciencesN/AN/A$-9,320,000.00($0.03)-110.67

Profitability

This table compares Lixte Biotechnology and Tiziana Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lixte BiotechnologyN/AN/AN/A
Tiziana Life SciencesN/AN/AN/A

Summary

Tiziana Life Sciences beats Lixte Biotechnology on 3 of the 3 factors compared between the two stocks.


Lixte Biotechnology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Neptune Wellness Solutions logo
NEPT
Neptune Wellness Solutions
1.3$1.62-1.9%$219.41 million$22.05 million-3.24
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
1.2$1.67-6.0%$214.44 million$40,000.00-0.41Increase in Short Interest
Strongbridge Biopharma logo
SBBP
Strongbridge Biopharma
1.5$3.08-2.6%$212.49 million$21.71 million-3.38Upcoming Earnings
News Coverage
Gap Down
Concert Pharmaceuticals logo
CNCE
Concert Pharmaceuticals
1.7$6.62-4.1%$211.17 million$1.08 million-2.58Earnings Announcement
Decrease in Short Interest
OptiNose logo
OPTN
OptiNose
1.6$3.96-1.3%$208.85 million$34.63 million-1.80Upcoming Earnings
Increase in Short Interest
Tiziana Life Sciences logo
TLSA
Tiziana Life Sciences
1.2$3.32-2.4%$208.07 millionN/A-110.67
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.4$3.09-4.9%$208.03 million$3.05 million-4.35Decrease in Short Interest
MDNA
Medicenna Therapeutics
0.7$3.98-1.0%$207.32 millionN/A-19.90Increase in Short Interest
scPharmaceuticals logo
SCPH
scPharmaceuticals
1.3$7.61-0.4%$207.09 millionN/A-4.70
Calithera Biosciences logo
CALA
Calithera Biosciences
1.7$2.90-0.0%$204.62 million$22.25 million-2.10News Coverage
Atossa Therapeutics logo
ATOS
Atossa Therapeutics
1.2$2.72-4.8%$203.99 millionN/A-2.01Decrease in Short Interest
Gap Down
Harrow Health logo
HROW
Harrow Health
1.7$7.99-1.0%$203.65 million$51.17 million-99.88Upcoming Earnings
News Coverage
Corbus Pharmaceuticals logo
CRBP
Corbus Pharmaceuticals
1.7$2.34-2.6%$201.69 million$36.14 million-1.31Increase in Short Interest
TLC
Taiwan Liposome
1.2$5.40-1.1%$200.32 million$6.99 million-6.75Decrease in Short Interest
ASLAN Pharmaceuticals logo
ASLN
ASLAN Pharmaceuticals
1.0$4.38-19.9%$199.45 million$3 million-4.06Increase in Short Interest
News Coverage
Gap Up
Lantern Pharma logo
LTRN
Lantern Pharma
1.2$18.06-4.7%$198.61 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$8.31-1.9%$197.34 million$460,000.00-6.98Upcoming Earnings
Gap Down
FSDC
FS Development
0.3$15.60-2.6%$195.25 millionN/A0.00
PANA
Panacea Acquisition
0.0$10.57-5.1%$195.08 millionN/A0.00
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.7$2.97-2.0%$192.21 millionN/A-2.11
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$9.55-1.4%$192.07 million$22.90 million-7.18Gap Down
Exicure logo
XCUR
Exicure
1.5$2.30-4.8%$191.84 million$1.30 million-8.85Upcoming Earnings
Gap Down
Heat Biologics logo
HTBX
Heat Biologics
1.6$7.84-4.5%$187.01 million$3.05 million0.00Upcoming Earnings
Equillium logo
EQ
Equillium
1.9$7.21-3.6%$184.91 millionN/A-4.59Increase in Short Interest
ObsEva logo
OBSV
ObsEva
1.4$3.88-0.8%$184.80 millionN/A-1.56Upcoming Earnings
vTv Therapeutics logo
VTVT
vTv Therapeutics
1.6$2.36-5.9%$184.70 million$2.76 million-5.36Earnings Announcement
Kindred Biosciences logo
KIN
Kindred Biosciences
1.5$4.56-0.4%$179.29 million$4.26 million-6.61
AcelRx Pharmaceuticals logo
ACRX
AcelRx Pharmaceuticals
1.3$1.92-2.9%$178.24 million$2.29 million-3.42Decrease in Short Interest
Aquestive Therapeutics logo
AQST
Aquestive Therapeutics
1.7$4.98-6.2%$177.85 million$52.61 million-3.25Upcoming Earnings
Analyst Revision
News Coverage
DiaMedica Therapeutics logo
DMAC
DiaMedica Therapeutics
1.5$9.14-1.9%$174.46 million$500,000.00-12.03
ENOB
Enochian Biosciences
0.3$3.65-0.3%$173.86 millionN/A0.00
GlycoMimetics logo
GLYC
GlycoMimetics
1.7$3.28-9.5%$171.71 millionN/A-2.90News Coverage
ORGS
Orgenesis
0.3$7.18-1.8%$170.30 million$33.26 million1.54Upcoming Earnings
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.6$3.46-0.3%$166.82 million$2.17 million-10.81Increase in Short Interest
News Coverage
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.99-1.2%$166.76 million$15.96 million-3.02Analyst Report
Analyst Revision
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$3.02-3.3%$166.68 million$380,000.000.00
Sierra Oncology logo
SRRA
Sierra Oncology
1.8$14.90-0.2%$164.18 millionN/A-1.07Increase in Short Interest
OncoSec Medical logo
ONCS
OncoSec Medical
1.6$5.80-1.6%$159.83 millionN/A-2.36
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$2.01-3.5%$155.91 millionN/A0.00Analyst Report
Biofrontera logo
BFRA
Biofrontera
1.2$6.24-4.2%$155.18 million$35.02 million-8.10Increase in Short Interest
Adamas Pharmaceuticals logo
ADMS
Adamas Pharmaceuticals
1.5$5.29-4.9%$153.76 million$54.64 million-2.39Decrease in Short Interest
Gap Down
Hepion Pharmaceuticals logo
HEPA
Hepion Pharmaceuticals
1.8$2.09-4.8%$151.69 millionN/A-0.35Increase in Short Interest
Gap Down
Adamis Pharmaceuticals logo
ADMP
Adamis Pharmaceuticals
1.1$1.12-0.4%$150.30 million$22.11 million-2.32Decrease in Short Interest
ContraFect logo
CFRX
ContraFect
1.4$5.36-0.2%$149.33 millionN/A-2.01Gap Down
Eyenovia logo
EYEN
Eyenovia
1.3$6.14-2.9%$148.31 millionN/A-5.58Analyst Report
Decrease in Short Interest
News Coverage
Gap Down
Liminal BioSciences logo
LMNL
Liminal BioSciences
1.1$4.66-7.3%$146.93 million$3.70 million-1.59Increase in Short Interest
Leap Therapeutics logo
LPTX
Leap Therapeutics
1.5$2.36-3.0%$144.97 millionN/A-2.17Analyst Report
Aptevo Therapeutics logo
APVO
Aptevo Therapeutics
0.9$33.10-1.8%$142.32 million$32.42 million-2.17News Coverage
Oncolytics Biotech logo
ONCY
Oncolytics Biotech
1.2$3.16-6.3%$139.98 millionN/A-3.90Upcoming Earnings
Decrease in Short Interest
Aytu BioScience logo
AYTU
Aytu BioScience
1.6$7.82-0.0%$139.85 million$27.63 million0.00
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.